Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism

Author： Erem Cihangir  

Publisher： Humana Press, Inc

ISSN： 0969-711X

Source： Endocrine Journal, Vol.35, Iss.1, 2009-02, pp. : 75-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

By  

Medical Principles and Practice, Vol. 20, Iss. 4, 2011-05 ,pp. : 332-335

Karger

Access to resources Recommend Favorite

Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI

By Erem Cihangir  

Endocrine Journal, Vol. 33, Iss. 3, 2008-06 ,pp. : 270-276

Humana Press, Inc

Access to resources Recommend Favorite

Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation

By Watanabe R.   Wada H.   Watanabe Y.   Sakakura M.   Nakasaki T.   Mori Y.   Nishikawa M.   Gabazza E.C.   Nobori T.   Shiku H.  

Thrombosis Research, Vol. 104, Iss. 1, 2001-10 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

Patients on Peritoneal Dialysis But Not on Hemodialysis Have Elevated Concentration and Activity of Thrombin-Activatable Fibrinolysis Inhibitor

By Hryszko T.   Malyszko J.   Malyszko J.S.   Brzosko S.   Mysliwiec M.  

Thrombosis Research, Vol. 104, Iss. 4, 2001-11 ,pp. : 233-238

Elsevier

Access to resources Recommend Favorite

Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome

By  

Cerebrovascular Diseases, Vol. 42, Iss. 5-6, 2016-07 ,pp. : 404-414

Karger

Access to resources Recommend Favorite